Abstract
Randomized clinical trials (RCTs) have informed the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, although challenges still exist. The evidence base for treating large-vessel vasculitis (LVV) is weaker, but initiatives to standardize diagnostic criteria and outcome measures, and to validate biomarkers in LVV, together with newly initiated RCTs should start to address this need. In this Perspectives, we discuss the prerequisites for RCTs in vasculitis, existing trial evidence, continuing unmet needs, potential therapeutic avenues to explore and considerations in the design of future trials.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Jennette, J. C. et al. 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 65, 1–11 (2013).
Hamour, S., Salama, A. D. & Pusey, C. D. Management of ANCA-associated vasculitis: current trends and future prospects. Ther. Clin. Risk Manag. 6, 253–264 (2010).
Robson, J. et al. Damage in the ANCA-associated vasculitides: long-term data from the European Vasculitis Study group (EUVAS) therapeutic trials. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2013-203927.
Heijl, C. et al. Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials. Ann. Rheum. Dis. 70, 1415–1421 (2011).
Unizony, S. H. et al. Design of the tocilizumab in giant cell arteritis trial. Int. J. Rheumatol. 2013, 912562 (2013).
US National Library of Medicine. Clinical trials.gov [online], (2013).
Walsh, M. et al. Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial. Trials 14, 73 (2013).
US National Library of Medicine. ClinicalTrials.gov [online], (2013).
Berry, D. A. Bayesian clinical trials. Nat. Rev. Drug Discov. 5, 27–36 (2006).
US National Library of Medicine. ClinicalTrials.gov [online], (2013).
Basu, N. et al. EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Ann. Rheum. Dis. 69, 1744–1750 (2010).
Craven, A. et al. ACR/EULAR-endorsed study to develop Diagnostic and Classification Criteria for Vasculitis (DCVAS). Clin. Exp. Nephrol. 17, 619–621 (2013).
Tervaert, J. W. et al. Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch. Intern. Med. 149, 2461–2465 (1989).
Seror, R. et al. Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2013-203586.
Berden, A. E. et al. Histopathologic classification of ANCA-associated glomerulonephritis. J. Am. Soc. Nephrol. 21, 1628–1636 (2010).
Merkel, P. A. et al. The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis. J. Rheumatol. 38, 1480–1486 (2011).
Direskeneli, H. et al. Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda. J. Rheumatol. 38, 1471–1479 (2011).
Luqmani, R. A. et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 87, 671–678 (1994).
de Groot, K., Gross, W. L., Herlyn, K. & Reinhold-Keller, E. Development and validation of a disease extent index for Wegener's granulomatosis. Clin. Nephrol. 55, 31–38 (2001).
Dolezalova, P. et al. Disease activity assessment in childhood vasculitis: development and preliminary validation of the Paediatric Vasculitis Activity Score (PVAS). Ann. Rheum. Dis. 72, 1628–1633 (2013).
Exley, A. R. et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum. 40, 371–380 (1997).
Suppiah, R. et al. Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index. Ann. Rheum. Dis. 70, 80–85 (2011).
Stone, J. H. et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N. Engl. J. Med. 363, 221–232 (2010).
Jones, R. B. et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N. Engl. J. Med. 363, 211–220 (2010).
Tarzi, R. M. & Pusey, C. D. Vasculitis: Risks and rewards of treating elderly patients with vasculitis. Nat. Rev. Nephrol. 7, 253–255 (2011).
Mello, M. M. et al. Preparing for responsible sharing of clinical trial data. N. Engl. J. Med. 369, 1651–1658 (2013).
Nisen, P. & Rockhold, F. Access to patient-level data from GlaxoSmithKline clinical trials. N. Engl. J. Med. 369, 475–478 (2013).
Fauci, A. S., Katz, P., Haynes, B. F. & Wolff, S. M. Cyclophosphamide therapy of severe systemic necrotizing vasculitis. N. Engl. J. Med. 301, 235–238 (1979).
Faurschou, M. et al. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J. Rheumatol. 35, 100–105 (2008).
Holle, J. U. et al. Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades. Arthritis Rheum. 63, 257–266 (2011).
Flossmann, O. et al. Long-term patient survival in ANCA-associated vasculitis. Ann. Rheum. Dis. 70, 488–494 (2011).
US National Library of Medicine. ClinicalTrials.gov [online], (2012).
Jennette, J. C., Falk, R. J., Hu, P. & Xiao, H. Pathogenesis of antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis. Annu. Rev. Pathol. 8, 139–160 (2013).
Hogan, S. L. et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann. Intern. Med. 143, 621–631 (2005).
Lyons, P. A. et al. Genetically distinct subsets within ANCA-associated vasculitis. N. Engl. J. Med. 367, 214–223 (2012).
Falk, R. J. & Jennette, J. C. ANCA disease: where is this field heading? J. Am. Soc. Nephrol. 21, 745–752 (2010).
de Groot, K. et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann. Intern. Med. 150, 670–680 (2009).
Harper, L. et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann. Rheum. Dis. 71, 955–960 (2012).
Jayne, D. R. et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J. Am. Soc. Nephrol. 18, 2180–2188 (2007).
Walsh, M. et al. Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney Int. 84, 397–402 (2013).
US National Library of Medicine. ClinicalTrials.gov [online], (2005).
Little, M. A. et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann. Rheum. Dis. 69, 1036–1043 (2010).
Watts, R. A., Lane, S. E., Bentham, G. & Scott, D. G. Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis Rheum. 43, 414–419 (2000).
Cohen, P. et al. Churg–Strauss syndrome with poor-prognosis factors: A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum. 57, 686–693 (2007).
Cartin-Ceba, R., Fervenza, F. C. & Specks, U. Treatment of antineutrophil cytoplasmic antibody-associated vasculitis with rituximab. Curr. Opin. Rheumatol. 24, 15–23 (2012).
Pepper, R. J. et al. Rituximab is effective in the treatment of refractory Churg–Strauss syndrome and is associated with diminished T-cell interleukin-5 production. Rheumatology (Oxford) 47, 1104–1105 (2008).
US National Library of Medicine. ClinicalTrials.gov [online], (2013).
Weyand, C. M., Liao, Y. J. & Goronzy, J. J. The immunopathology of giant cell arteritis: diagnostic and therapeutic implications. J. Neuroophthalmol. 32, 259–265 (2012).
Mason, J. C. Takayasu arteritis—advances in diagnosis and management. Nat. Rev. Rheumatol. 6, 406–415 (2010).
US National Library of Medicine. ClinicalTrials.gov [online]. (2009).
Diamantopoulos, A. P. et al. Diagnostic value of color Doppler ultrasonography of temporal arteries and large vessels in giant cell arteritis: a consecutive case series. Arthritis Care Res. (Hoboken) 66, 113–119 (2014).
Misra, R. et al. Development and initial validation of the Indian Takayasu Clinical Activity Score (ITAS2010). Rheumatology (Oxford) 52, 1795–1801 (2013).
Hoffman, G. S. et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann. Intern. Med. 146, 621–630 (2007).
Martinez-Taboada, V. M. et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann. Rheum. Dis. 67, 625–630 (2008).
Mahr, A. D. et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum. 56, 2789–2797 (2007).
Hoffman, G. S. et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum. 46, 1309–1318 (2002).
Jover, J. A. et al. Combined treatment of giant-cell arteritis with methotrexate and prednisone. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 134, 106–114 (2001).
Spiera, R. F. et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin. Exp. Rheumatol. 19, 495–501 (2001).
Dasgupta, B. et al. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology (Oxford) 49, 1594–1597 (2010).
US National Library of Medicine. ClinicalTrials.gov [online], (2013).
Comarmond, C. et al. Anti TNF-α in refractory Takayasu's arteritis: cases series and review of the literature. Autoimmun. Rev. 11, 678–684 (2012).
Abisror, N. et al. Tocilizumab in refractory Takayasu arteritis: a case series and updated literature review. Autoimmun. Rev. 12, 1143–1149 (2013).
Youngstein, T. et al. Serial analysis of clinical and imaging indices reveals prolonged efficacy of TNF-α and IL-6 receptor targeted therapies in refractory Takayasu arteritis. Clin. Exp. Rheumatol. CER6558 (2013).
De Groot, K. et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 52, 2461–2469 (2005).
Faurschou, M. et al. Brief report: long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 64, 3472–3477 (2012).
Specks, U. et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N. Engl. J. Med. 369, 417–427 (2013).
Jayne, D. et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N. Engl. J. Med. 349, 36–44 (2003).
Hiemstra, T. F. et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA 304, 2381–2388 (2010).
Pagnoux, C. et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N. Engl. J. Med. 359, 2790–2803 (2008).
The Wegener's granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N. Engl. J. Med. 352, 351–361 (2005).
Metzler, C. et al. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology (Oxford) 46, 1087–1091 (2007).
Acknowledgements
R.M.T. gratefully acknowledges salary support from an Arthritis Research UK Clinician Scientist Fellowship. The authors acknowledge support from the Imperial NIHR Biomedical Research Centre.
Author information
Authors and Affiliations
Contributions
R.M.T. and J.C.M. researched data for and wrote the article. All authors made equal contributions to discussion of content and reviewing/editing the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
C.D.P. has received a research grant from GlaxoSmithKline. R.M.T. and J.C.M. declare no competing interests.
Supplementary information
Rights and permissions
About this article
Cite this article
Tarzi, R., Mason, J. & Pusey, C. Issues in trial design for ANCA-associated and large-vessel vasculitis. Nat Rev Rheumatol 10, 502–510 (2014). https://doi.org/10.1038/nrrheum.2014.67
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2014.67
This article is cited by
-
Randomized clinical trials in ANCA-associated vasculitis: a systematic analysis of the WHO - International Clinical Trials Registry Platform
Orphanet Journal of Rare Diseases (2020)
-
Three days of high-dose glucocorticoid treatment attenuates large-vessel 18F-FDG uptake in large-vessel giant cell arteritis but with a limited impact on diagnostic accuracy
European Journal of Nuclear Medicine and Molecular Imaging (2018)